藥石科技(300725.SZ)擬1.65億元收購浙江暉石16.5%股權
格隆匯3月25日丨藥石科技(300725.SZ)公佈,基於公司產業戰略發展規劃,整合吸收優質資源,實現公司業務的健康快速發展,公司於2021年3月25日與浙江暉石藥業有限公司(“浙江暉石”或“目標公司”)的股東重慶博騰製藥科技股份有限公司(“博騰股份”)簽署了《南京藥石科技股份有限公司與重慶博騰製藥科技股份有限公司關於浙江暉石藥業有限公司之股權轉讓協議》、與浙江暉石的股東寧波美諾華藥業股份有限公司(“寧波美諾華”)簽署了《南京藥石科技股份有限公司與寧波美諾華藥業股份有限公司關於浙江暉石藥業有限公司之股權轉讓協議》。
公司將以現金方式收購浙江暉石16.5%股權(對應的浙江暉石註冊資本額為人民幣8250萬元),此次交易金額合計為人民幣1.65億元。此次交易完成後,公司持有的浙江暉石股權比例將由37.43%變更為53.93%,浙江暉石將成為公司的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.